GI
CLDX icon

GAMMA Investing’s Celldex Therapeutics CLDX Stock Holding History

GAMMA Investing’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.6K Buy
697
+341
+96% +$13K ﹤0.01% 2874
2026
Q2 		$13.2K Buy
356
+80
+29% +$2.58K ﹤0.01% 3062
2026
Q1 		$8.76K Buy
276
+54
+24% +$1.47K ﹤0.01% 3137
2025
Q4 		$6.03K Buy
222
+81
+57% +$2.13K ﹤0.01% 3199
2025
Q3 		$3.65K Buy
141
+71
+101% +$1.65K ﹤0.01% 3293
2025
Q2 		$1.43K Sell
70
-94
-57% -$1.83K ﹤0.01% 3468
2025
Q1 		$2.98K Buy
164
+120
+273% +$2.68K ﹤0.01% 3279
2024
Q4 		$1.11K Sell
44
-7
-14% -$190 ﹤0.01% 3397
2024
Q3 		$1.73K Buy
51
+41
+410% +$1.56K ﹤0.01% 3115
2024
Q2 		$370 Sell
10
-14
-58% -$528 ﹤0.01% 3254
2024
Q1 		$1.01K Buy
+24
New +$986 ﹤0.01% 2942

Other funds holding CLDX

MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return
OMC
Overbrook Management Corp New York $643M AUM 29.06% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's CLDX Position: Q3 2026 in Review

GAMMA Investing increased its Celldex Therapeutics (CLDX) stake by 96% in Q3 2026, buying an estimated $13K and bringing the position to 697 shares worth $22.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2874.

GAMMA Investing first reported a position in CLDX in Q1 2024 and has held it in 11 quarters since. 7 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • GAMMA Investing held 697 shares of Celldex Therapeutics worth $22.6K as of Q3 2026.
  • GAMMA Investing bought 341 Celldex Therapeutics shares in Q3 2026, an estimated $13K.
  • Celldex Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2874 holding.
  • GAMMA Investing first reported a position in Celldex Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 7 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.